National Comprehensive Cancer Network

About NCCN

NCCN Guidelines and Compendium Updated

Flash Update Sent January 6, 2012
NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Distress Management. These NCCN Guidelines® are currently available as Version 1.2012.

  • Throughout the Distress Management Guidelines, the recommendation "Follow-up and communication with primary oncology team" was changed to "Follow-up and communication with primary oncology team and family/caregivers."
  • Expected Distress Symptoms: The following was added "Concerns about social role (ie, as father, mother)."
  • Dementia: For patients with no response to cognitive rehabilitation with or without medications, the recommendation "Attend to patient safety" was added.
  • Delirium: For patients with no response to neuroleptics + family support/education, the recommendation "Re-evaluate cause of delirium" was added.
  • Adjustment Disorder: For patients evaluated as "Danger to self or others", the following recommendations were added: "Consider psychiatric consultation, Increase monitoring, Consider removing sharp objects."
  • Substance-Related Disorder/Abuse: For patients with a history of abuse, the recommendation "Monitor for signs and symptoms of relapse" was added.
  • Chaplaincy Services:
    • Isolation from Religious Community: For patients who are not current members of a religious community and who receive a spiritual assessment, the following recommendation was added "Assist patient to access spiritual resources."
    • Hopelessness: For patients with or without "Severe depressive symptoms and/or suicidal ideation", the following recommendation was added: "Palliative/supportive care consultation."
    • Ritual Needs: For patients who have evidence of ritual needs, the following recommendation was added, "Chaplain provides ritual if appropriate."

Flash Update Sent January 12, 2012
NCCN has published updates to the NCCN Drugs & Biologics Compendium (NCCN Compendium®) to reflect updates to the 2012 version of the corresponding NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®):

  • Bladder Cancer V.2.2012
    • Bladder Cancer
    • Upper GU Tract Tumors
    • Urothelial Carcinoma of the Prostate
  • Myelodysplastic Syndromes V.1.2012


Flash Update Sent January 19, 2012
NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Bone Cancer. These NCCN Guidelines® are currently available as Version 2.2012.

  • The Discussion section was updated to reflect the changes in the algorithm.


NCCN has published updates to the NCCN Guidelines for Colon and Rectal Cancers. Both NCCN Guidelines are currently available as Version 3.2012.

  • There was a dosage change for bevacizumab in the regimen, capecitabine + bevacizumab, which is a treatment option for advanced or metastatic disease.
  • A reference was added for the capecitabine/oxaliplatin (CapeOx) + bevacizumab regimen and capecitabine + bevacizumab regimen: Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26:2013-2019. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18421054

NCCN has published updates to the NCCN Guidelines and the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Hodgkin Lymphoma. These NCCN Guidelines are currently available as Version 1.2012.

  • Interim staging recommendations changed from PET-CT to CT through regions of initial disease for Stage IA, IIA, favorable classical Hodgkin lymphoma.
  • The recommended number of cycles of ABVD changed from 2 to 4 in the primary treatment for Stage I-II, unfavorable disease.
  • A footnote was added to the lymphocyte-predominant Hodgkin lymphoma (LPHL) primary treatment recommendations, "In some patients treated with rituximab alone, maintenance rituximab may be considered for 2 years."
  • Recommendations clarified and expanded to address the timing of transplant and additional therapy for suspected relapse and progressive disease.
  • A clarifying statement that therapy with either protons or photons is acceptable was added to the Principles of Radiation Therapy section.
  • Bendamustine added as a treatment option for second-line chemotherapy.
  • A clarifying statement that rituximab should be considered with all regimens for relapsed LPHL was added to the Principles of Second-line Chemotherapy section.

 

NCCN has published updates to the NCCN Guidelines and the NCCN Compendium® for Testicular Cancer. These NCCN Guidelines are currently available as Version 1.2012.

  • For patients with seminoma Stages I and II, the follow-up after primary treatment was extensively revised.
  • A new section titled, "Principles of Radiotherapy for Pure Testicular Seminoma" was added.
  • The following were added to the list of palliative chemotherapy regimens:
    • Gemcitabine/paclitaxel
    • Gemcitabine/paclitaxel/oxaliplatin
  • The Discussion section was updated to reflect the changes in the algorithm.


For the complete updated version of these and all NCCN Guidelines, visit NCCN.org.